Acurx reports Q3 net loss of $3.5M; cash $10.6M; Phase 2b enrollment continues

Acurx Pharmaceuticals, Inc.

2022-Q3 EPS reported -$0.84

Net loss of $3.5M ($0.32 per diluted share) for Q3 2022, vs $4.6M ($0.46) in Q3 2021.
Cash and cash equivalents $10.6M as of Sep 30, 2022, down from $13.0M at Dec 31, 2021.
Phase 2b trial for C. difficile infection enrollment ongoing; added sites, expecting up to 30 total.
Raised $4.225M in July 2022 via registered direct offering to institutional investor and executives.
R&D expenses $1.6M in Q3 2022 vs $1.1M in Q3 2021, increase due to Phase 2b costs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Acurx Pharmaceuticals, Inc. reported the quarter ended September 30, 2022 results: net income net loss of $3.5 million, EPS $0.32 per diluted share.

Period: the quarter ended September 30, 2022
Net income: net loss of $3.5 million
EPS: $0.32 per diluted share
Result: reported results

Exact text from the filing

The Company reported a net loss of $3.5 million or $0.32 per diluted share for the three months ended September 30, 2022

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Acurx Pharmaceuticals, Inc. reported the nine months ended September 30, 2022 results: net income net loss of $8.8 million, EPS $0.84 per share.

Period: the nine months ended September 30, 2022
Net income: net loss of $8.8 million
EPS: $0.84 per share
Result: reported results

Exact text from the filing

a net loss of $8.8 million or $0.84 per share for the nine months ended September 30, 2022

View on SEC.gov

Browse all earnings releases →

Acurx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-117682

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.